Metopocor (Metoprolol Tartrate)

• Metopocor, a beta‑adrenergic blocker, is used in several cardiovascular disease pathways to control blood pressure and cardiac workload.
• Hypertension: reduces systolic and diastolic pressure, lowering risk of stroke and organ damage.
• Angina pectoris: alleviates chest pain by decreasing myocardial oxygen demand.
• Acute myocardial infarction: improves survival by lowering heart rate and workload during the acute phase.
• Heart failure: enhances ventricular function and reduces symptoms of fluid overload.
• Cardiac arrhythmias: stabilizes abnormal rhythms by slowing AV‑node conduction.

• Metoprolol tartrate selectively binds to β1‑adrenergic receptors located primarily in cardiac tissue. By blocking catecholamine stimulation of these receptors, it diminishes cyclic AMP formation, leading to reduced intracellular calcium influx. The resulting effect is a decrease in heart rate (negative chronotropy), contractile force (negative inotropy), and overall cardiac output, which helps lower arterial pressure and myocardial oxygen consumption.

Metopocor may be associated with a range of adverse reactions, varying from mild to severe, and patients should be monitored.

Common Side Effects

• Fatigue or tiredness: feeling unusually weak or lacking energy.
• Dizziness or light‑headedness: sensation of unsteadiness, especially when standing quickly.
• Cold extremities: reduced blood flow causing hands and feet to feel cool.
• Gastrointestinal discomfort: nausea, abdominal pain or mild upset stomach.
• Headache: mild to moderate head pain that may improve with rest.

Serious or Rare Side Effects

• Severe bradycardia: heart rate falls below 40 beats per minute, potentially causing fainting.
• Hypotensive crisis: sudden, marked drop in blood pressure that may lead to shock.
• Bronchospasm or worsening asthma: constriction of airways causing breathing difficulty.

When prescribing Metopocor, clinicians should observe several precautionary measures to ensure safe use.

• Cardiovascular assessment: evaluate heart rate, blood pressure and cardiac function before initiation.
• Concomitant β‑blocker therapy: avoid combining with other β‑blockers to prevent excessive bradycardia.
• Respiratory disease: use cautiously in patients with asthma or chronic obstructive pulmonary disease.
• Diabetes mellitus: monitor blood glucose as β‑blockade may mask hypoglycaemia symptoms.
• Store at room temperature: keep in original container, protect from moisture and light.

Metopocor can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Non‑selective β‑blockers: concurrent use may cause profound bradycardia and hypotension.
• Calcium channel blockers (verapamil, diltiazem): combined therapy increases risk of heart block and severe hypotension.

Moderate Interactions (Monitor Closely)

• Antidiabetic agents: β‑blockade may mask hypoglycaemia signs, requiring glucose monitoring.
• Antidepressants (SSRIs, SNRIs): may enhance bradycardic effects.
• NSAIDs: can reduce antihypertensive effect of Metopocor.